Daniel Pollyea, MDEnriched profile
Professor of Medicine; Clinical Director of Leukemia Services; Robert H. Allen MD Endowed Chair in Hematology Research; Interim Chief, Division of Hematology, Department of Medicine, University of Colorado School of Medicine · University of Colorado Anschutz Medical Campus
Overview
Updated 14 Jul 2026
Daniel A. Pollyea, MD, is Professor of Medicine at University of Colorado School of Medicine / University of Colorado Cancer Center (Aurora, CO). The public record shows 558 publications with 25,464 citations (h-index 70), centered on Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Acute Lymphoblastic Leukemia research. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 24 companies, 2 NIH-funded awards (2024–2026).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Acute Myeloid Leukemia Research
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 24 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 37 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 173.
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)
Sponsor: University of Colorado, Denver
InvestigatorPhase 2RecruitingNCT07579429 - Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
Sponsor: University of Colorado, Denver
InvestigatorPhase 1RecruitingNCT06429449 - KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia
Sponsor: University of Colorado, Denver
InvestigatorPhase 1CompletedNCT04914845
Industry payments
Updated 14 Jul 2026
24 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- SERVIER PHARMACEUTICALS LLCProgram year20258 payments
- ABBVIE INC.Program year20259 payments
- Geron CorporationProgram year20256 payments
NIH funding
Updated 14 Jul 2026
2 NIH research awards on record, funded 2024–2026 per NIH RePORTER. The latest:
- IAP inhibition as a therapeutic strategy to target therapy-resistant leukemia initiating cells
University of Colorado Denver
FY2026$387,630R01CA292432 - Targeting mitochondrial calcium to eradicate leukemia-initiating cells
University of Colorado Denver
FY2025$437,432R01CA292071 - IAP inhibition as a therapeutic strategy to target therapy-resistant leukemia initiating cells
University of Colorado Denver
FY2025$387,630R01CA292432
Congress activity
Updated 14 Jul 2026
128 congress contributions (2010–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Real-world patient management practices in responders to venetoclax for newly diagnosed acute myeloid leukemia.
ASCO Annual Meeting
ASCO2025Co-author - Tolerability and outcomes with serial cycles of 28 days of venetoclax in newly diagnosed patients with AML.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
Journal of clinical oncology
2026 - RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcoma.
Blood cancer discovery
2026 - Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia.
American journal of hematology
2026
Most-cited worksby citation count (OpenAlex)
- 01
- 02Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia1,474 citations2017
- 03Functional genomic landscape of acute myeloid leukaemia1,462 citations2018
- 04
- 05
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
1665 Aurora Court, Room 4332, MS F704, Aurora, CO 80045
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
Editorial & leadership rolesjournal and society appointments
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- National Comprehensive Cancer Network (NCCN)
AML Guidelines Committee, Member (2013–present), Vice-Chairman (2019–2021), Chairman
2021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
Secondary affiliationsappointments beyond the home institution
- University of Colorado Hospital / UCHealth Blood Disorders and Cell Therapies Center
affiliated hospital / clinical practice site
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cumedicine.us ↗ - American Society of Hematology
professional membership
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗ - American Society of Clinical Oncology
professional membership
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
Media & interviewspress, podcasts and appearances
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
- Research To Practice video podcast series
Daniel A. Pollyea, MD, MS on Acute Myeloid Leukemia
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →videopodcast.researchtopractice.com ↗ - The Hematology Podcast Series
recurring guest discussing AML classification and trial data (e.g., ELN classification episode with Dr. Brian Leber)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- ResearchGate
researchgate.net/profile/Daniel-Pollyea
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by otherswhere others cite or feature them
- LinkedIn
linkedin.com/posts/thomas-flaig-md-cuanschutz_daniel-pollyea-md-ms-recognized-by-the-activity-7292269690268041216-2Tgd
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - X / Twitter
X (Twitter) account @DanPollyea
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kevin Deane, MD
University of Colorado Anschutz Medical Campus
- 253
- publications
- 61
- h-index
- 2
- trials
Gregory Forlenza, MD
University of Colorado Anschutz Medical Campus
- 295
- publications
- 58
- h-index
- 9
- trials